Abstract 5864
Background
Cancer is considered a traumatic event that can lead to post-traumatic stress disorder. Significant changes are taking place in the life, body image, lifestyle and social life of the individual diagnosed with cancer. Therefore, they are faced with a psychological and physiological difficult process. In the researches, it was found that the attachment styles that individuals will experience in their lifelong relationships are one of the important predictors of psychological resilience. The aim of our study is to examine the relationship between psychological resilience and adult attachment styles among cancer patient individuals receiving chemotherapy.
Methods
A total of 391 volunteer patients receiving chemotherapy were included from Dr. A.Y. Ankara Oncology Research and Training Hospital and Ankara Güven Hospital in the study. The inventories used in the data collection phase of the study are Relationship Scales Questionnaire, Resilience Scale for Adults and a personal information form that is produced by researcher. Datasare analyzed with SPSS 23.00.
Results
In our results, 285 (73%) of the patients were female and the median age was 53 (20-83). The median endurance score was 130 (49-165). The patients were divided into median values to be less resistant and resistant. The age, gender, marital status, working status, educational status, economic status, who they experienced, who they grew up with, their social support, trust in chemotherapy and dominant attachment styles were compared with univariate analysis. there were four style of attachments; secure, avoidant, fearful, preoccupied. Secure attachment was at half of patients (n = 191,48.8%) while avoidant attachment was at 159 (40.6%) patients. The other attachment styles were seen significantly less.
As a result of multivariate analysis, the patient’s social support is moderate or bad; lack of confidence in chemotherapy, the presence of avoidant or fearful attachment was found to be independent negative factors affecting the resilience of the patient.
Conclusions
Avoidant and fearful attachment have a significant negative impact on the resilience of the patients receiving chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fatma Bugdayci Basal.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5751 - Phase 3 ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)−positive non–small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
Presenter: Sanjay Popat
Session: Poster Display session 1
Resources:
Abstract
5103 - CANOPY phase 3 program: Three studies evaluating canakinumab in patients with non-small cell lung cancer (NSCLC)
Presenter: Luis Paz-Ares
Session: Poster Display session 1
Resources:
Abstract
3666 - The Elderly Patient Individualized Chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer.
Presenter: Francesco Passiglia
Session: Poster Display session 1
Resources:
Abstract
4799 - KEYNOTE-495/KeyImPaCT: A Randomized, Biomarker-Directed, Phase 2 Trial of Pembrolizumab-Based Therapy for Non–Small Cell Lung Cancer (NSCLC)
Presenter: Martin Gutierrez
Session: Poster Display session 1
Resources:
Abstract
6035 - Safety, tolerability and activity of autologous T cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non small cell lung cancer: A Phase 1b/2a randomised pilot study
Presenter: Karen Reckamp
Session: Poster Display session 1
Resources:
Abstract
2176 - IFCT-1701 DICIPLE: a randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment
Presenter: Gerard Zalcman
Session: Poster Display session 1
Resources:
Abstract
2352 - ATALANTE-1 randomized phase 3 trial, OSE-2101 versus standard treatment as second or third line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients
Presenter: Enriqueta Felip
Session: Poster Display session 1
Resources:
Abstract
2451 - Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours
Presenter: Nicolas Girard
Session: Poster Display session 1
Resources:
Abstract
4285 - Radiosurgery followed by Tumor Treating Fields (TTFields) for brain metastases (1-10) from NSCLC in the phase 3 METIS trial
Presenter: Minesh Mehta
Session: Poster Display session 1
Resources:
Abstract
4909 - Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): the SQUINT trial
Presenter: Lorenza Landi
Session: Poster Display session 1
Resources:
Abstract